254 related articles for article (PubMed ID: 3932640)
1. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
Breese GR; Baumeister A; Napier TC; Frye GD; Mueller RA
J Pharmacol Exp Ther; 1985 Nov; 235(2):287-95. PubMed ID: 3932640
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
3. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
4. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
[TBL] [Abstract][Full Text] [Related]
5. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors.
Criswell HE; Mueller RA; Breese GA
Eur J Pharmacol; 1989 Jan; 159(2):141-7. PubMed ID: 2495973
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.
Criswell HE; Mueller RA; Breese GR
Neuropsychopharmacology; 1992 Sep; 7(2):95-103. PubMed ID: 1418306
[TBL] [Abstract][Full Text] [Related]
8. Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels.
Nowak P; Dabrowska J; Bortel A; Biedka I; Szczerbak G; Słomian G; Kostrzewa RM; Brus R
Eur J Pharmacol; 2006 Dec; 552(1-3):46-54. PubMed ID: 17055481
[TBL] [Abstract][Full Text] [Related]
9. SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons.
Breese GR; Mueller RA
Eur J Pharmacol; 1985 Jul; 113(1):109-14. PubMed ID: 2864260
[TBL] [Abstract][Full Text] [Related]
10. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats.
Criswell H; Mueller RA; Breese GR
J Neurosci; 1989 Jan; 9(1):125-33. PubMed ID: 2521511
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
12. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine.
Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842
[TBL] [Abstract][Full Text] [Related]
13. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
Sivam SP; Breese GR; Krause JE; Napier TC; Mueller RA; Hong JS
J Neurochem; 1987 Nov; 49(5):1623-33. PubMed ID: 2889804
[TBL] [Abstract][Full Text] [Related]
14. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.
Arnt J; Hyttel J
Psychopharmacology (Berl); 1985; 85(3):346-52. PubMed ID: 2860689
[TBL] [Abstract][Full Text] [Related]
15. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions.
Arnt J
Life Sci; 1985 Aug; 37(8):717-23. PubMed ID: 3927097
[TBL] [Abstract][Full Text] [Related]
17. Assessment of purine-dopamine interactions in 6-hydroxydopamine-lesioned rats: evidence for pre- and postsynaptic influences by adenosine.
Criswell H; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1988 Feb; 244(2):493-500. PubMed ID: 3126293
[TBL] [Abstract][Full Text] [Related]
18. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.
Trugman JM; Wooten GF
J Neurosci; 1987 Sep; 7(9):2927-35. PubMed ID: 3114439
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behaviour in the rabbit.
Ongini E; Caporali MG
Neuropharmacology; 1987 Apr; 26(4):355-60. PubMed ID: 2953987
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
